Introduction
Although the incidence of tuberculosis (TB) is declining in most European Union (EU) countries, notification rates in Romania, despite recent progress, are several times higher than the European mean of 13.5 per 100 000. Romania is one of the 18 TB high-priority countries within the World Health Organization (WHO) European Region [1] . In 2015, out of the 60 195 TB cases reported by the 30 EU/European Economic Area (EEA) countries, one-quarter were from Romania [2] .
The number of injecting drug users (IDUs) in the general Romanian population has increased by almost 9% since 2007 [3] . Its geographical location means that Romania is part of the Balkan route for heroin trafficking. Moreover, in the last few years a new "legal drugs" market has arisen, with increasing use of psychoactive drugs, known as "ethnobotanicals". These are derived from cathinones and are a mixture of chemical powders such as mephedrone, methylenedioxypyrovalerone (MDPV), 5-MeO-DALT, phenetylamine and benzopyrene. Ethnobotanicals have psychoactive effects similar to those produced Correspondence: Dr Cristiana Oprea, Carol Davila University of Medicine and Pharmacy, 37 Dionisie Lupu Street, Bucharest 030167, Romania. Tel: +40213180719; Fax: +40213180721; e-mail: cristiana.oprea@ spitalulbabes.ro by amphetamines. These drugs are commercialized as "spice-type" smoking drugs or synthetic psychoactive substances that can be injected or sniffed [3] . They are cheap and therefore affordable for most IDUs. They are also highly addictive and require multiple injections (6-10 times/day); thus, the risk of acquiring bacterial and viral infections with their use is very high [3] [4] [5] [6] [7] .
By the end of 2014, there were 12 886 people living with HIV/AIDS (PLWH) in Romania. The number of newly diagnosed cases per year has increased progressively, from 445 in 2007 to > 900 in 2014 [8] . While the majority of HIV/AIDS cases reported during the 1990s arose from the cohort of children infected via the parenteral mode in the late 1980s, the HIV epidemic in Romania nowadays follows the general European trend, with an increasing incidence in IDUs and men who have sex with men (MSM). In 2007, IDUs accounted for 2% of new cases of HIV infection, but by 2014 this had increased to > 20%, associated with a concomitant spread of hepatitis B and C and severe cases of systemic bacterial infections [8] [9] [10] [11] . In addition, in 2014, 16% of Romanian IDUs diagnosed with HIV infection also had pulmonary TB [9] .
The "Victor Babes" Clinical Hospital for Infectious Diseases (SVB), Bucharest, is a tertiary referral centre which manages a large national case-load of known HIVinfected IDUs. The aims of our study were: to determine the prevalence of TB among IDUs newly diagnosed with HIV infection admitted to SVB; to describe their demographic and clinical characteristics according to TB coinfection status; and to consider the impact of TB coinfection, TB drug resistance and site of disease on mortality.
Methods

Patient population
We performed a prospective study of adult IDUs with HIV infection admitted to SVB between January 2009 and December 2014. It is standard practice in Romania for people who inject drugs to be admitted to the HIV department at the time of HIV diagnosis. HIV testing is mandatory for all new TB diagnoses, and all patients with suspected or diagnosed TB are also hospitalized. Therefore, almost all IDUs diagnosed with TB who are HIV positive are managed in our service, plus > 90% of those with HIV monoinfection. Social, demographic and clinical characteristics were obtained from clinical databases from the time of admission until the date of last follow-up at 31 December 2015.
All patients satisfying study criteria gave informed consent to participate in this study.
Tuberculosis diagnosis and disease classification
TB diagnosis was classified as definitive [positive mycobacterial cultures, molecular tests, Mycobacterium tuberculosis (MTB) polymerase chain reaction (PCR) and histopathological examination] or presumptive (based on clinical and radiological findings, and response to empirical treatment). Clinical forms of TB were categorized as pulmonary TB, extra-pulmonary TB and disseminated TB (in patients with both pulmonary and extra-pulmonary involvement).
In line with recommended definitions, a CD4 cell count < 350 cells/lL at the time of HIV diagnosis was considered to indicate late presentation (LP) and a CD4 count < 200 cells/lL was considered to indicate advanced HIV disease (AHD) [12, 13] .
Statistical analysis
Individuals were followed from the date of HIV diagnosis until the time of death or last follow-up at 31 December 2015. The prevalence of TB coinfection at or immediately after HIV diagnosis was summarized by calendar year, and investigated using a test for trend. Demographic and clinical characteristics at the time of HIV diagnosis were compared according to TB 
Results
Comparison of HIV-infected IDUs with and without TB
A total of 598 IDUs were diagnosed with HIV infection, with a median follow-up of 30.0 [interquartile range (IQR) 17.8, 42.1] months. One hundred and seventy (28.5%) were also diagnosed with active TB, of whom 153 (90%) had a simultaneous diagnosis of both HIV infection and TB. The remaining 17 of 170 (10%) were diagnosed with TB a median of 140 (IQR 100, 284) days after HIV diagnosis. TB prevalence among HIV-infected IDUs rose dramatically from 2009 to 2013, with a slight decrease in 2014 (P < 0.001) (Fig. 1) .
The majority of IDUs were young, from urban areas and male (Table 1 ). There were no differences according to TB coinfection status with respect to gender, age at HIV diagnosis and median duration of injecting drug use. A significantly higher proportion of the HIV/TB-coinfected IDUs were unemployed and had a low educational level compared with HIV-infected IDUs without TB. A history of multiple sexual partners/unprotected sexual intercourse was significantly more common in IDUs without TB.
About one-third of the patients, irrespective of TB status, had used drugs for > 10 years. Few reported starting drug use within the last 12 months [2.3% (4/170) of IDUs with TB versus 3.9% (17/428) of those without TB; P = 0.33]. The majority of IDUs injected both heroin and psychoactive drugs. However, TB-coinfected patients were more likely to use ethnobotanicals exclusively or in combination with other smoked drugs, whereas heroin use alone or in combination with other psychoactive drugs was more commonly reported in those without TB (Table 1) .
HIV infection status and viral hepatitis coinfection
Blood CD4 cell count at HIV diagnosis was available for 84.6% (506) of IDUs: 100% (170 of 170) of those with TB and 78.5% (336 of 428) of those without TB. HIV viral load was available in 36.8% (220) of IDUs: 33.5% (57) of those with TB and 38.1% (163) of those without TB. The median CD4 cell count at HIV diagnosis was lower for IDUs with TB compared with non-TB IDUs: 75 vs. 450 cells/lL, respectively (P < 0.0001) ( Table 2 ). In addition, a significantly higher percentage of IDUs who developed TB were diagnosed as late presenters (CD4 count < 350 cells/lL) compared with the non-TB IDUs (P < 0.0001). Even so, 26 patients (15.2%) developed TB with a blood CD4 count > 500 cells/lL. Among those who had injected drugs for more than 10 years, HIV/TB-coinfected IDUs had more severe immunosuppression (median CD4 count 51 vs. 478 cells/lL in those without TB; P < 0.0001). The median HIV viral load at HIV diagnosis was higher for HIV/TBcoinfected patients than for HIV-monoinfected patients (5.6 vs. 4.9 log 10 HIV-1 RNA copies/mL, respectively; P = 0.0002). Almost all IDUs (90.0%; 198 of 220) had a HIV viral load > 10 5 copies/mL ( Table 2 ).
Irrespective of their TB status, most patients were coinfected with hepatitis C virus (HCV) (98.3%; 588). IDUs without TB were more likely to be hepatitis B virus surface antigen (HBsAg) positive (Table 2 ; P = 0.004). Overall, antiretroviral treatment (ART) was ever initiated in 30.1% (180) of patients, with a higher percentage starting in the TB-coinfected subgroup (P < 0.0001). bronchial aspirate. TB diagnosis was established only by MTB-PCR in 6 of 170 (3.5%) cases, from sputum and bronchial aspirate in four cases and from CSF in two cases. There were also nine of 170 (5.2%) patients who had both positive cultures and MTB-PCR (lymph nodes, four patients; CSF, three; ascites, one; pleural fluid, one). In the remaining 65 of 170 cases (38.2%), the diagnosis was presumptive.
Clinical characteristics of HIV-infected IDUs with TB
The majority of IDUs diagnosed with TB developed pulmonary disease 60.6% (103/170), more than a quarter 28.8% (49/170) had disseminated disease and 10.5% (18/170) had extra-pulmonary disease. Among patients with extra-pulmonary TB, 10 were diagnosed with TB meningoencephalitis, six with intestinal TB, one with osteo-articular TB and one with hepatosplenic TB. 
Time to death according to presence of TB
A total of 72 individuals died (12%), comprising 23.5% (40 of 170) of those with TB compared with 7.4% (32 of 428) of those without (P < 0.0001) (Fig. 2a) Time to death according to site of TB disease and presence of TB drug resistance Considering the subgroup coinfected with both HIV and TB, the incidence of early (within 3 months of diagnosis) and late (from 3 months onwards) mortality was higher in IDUs with extra-pulmonary TB, and those with XDR TB strains (Table 3) . These results were corroborated in Kaplan-Meier plots demonstrating different survival times according to the site of TB disease (P = 0.0026; Fig. 2b ) and the presence of a drug-resistant strain (P = 0.024; Fig. 2c ).
Discussion
In 2015, there were 15 195 cases of TB in Romania, giving a notification rate of 76.5 per 100 000 inhabitants [2] . TB is one of the commonest opportunistic infections associated with HIV infection [8] . Among TB cases nationally, the HIV incidence per 100 people has risen from 0.11 in 1990 to 0.93 in 2014, with a peak of 1.37 in 2011 [8] . In our prospective study, we report an approximately twofold increase in the prevalence of HIV/TB coinfection in IDUs presenting at a Romanian tertiary care centre between 2009 and 2014. The majority of patients were diagnosed with both HIV and TB simultaneously, and had advanced HIV infection.
It has been previously shown that PLWH with lower CD4 counts are more likely to develop TB compared with people with better immune status at HIV diagnosis [14, [16] [17] [18] . Similar to data reported annually from European Centre for Disease Prevention and Control (ECDC) [2] , we found pulmonary TB to be the most frequent clinical form of disease. However, extra-pulmonary TB was associated with more severe immunosuppression and a higher mortality, probably as a result of over half of these patients presenting with TB meningitis.
The mortality rate in our study was higher for IDUs diagnosed with TB. This is in line with other European reports which also found a greater risk of death in patients with TB, in particular during the first year following HIV diagnosis [15] . Among IDUs with TB, the mortality rate was greatest in those with extra-pulmonary disease and people with XDR TB.
Although ART increases survival in HIV/TB-coinfected patients [19] , delay in its initiation, itself often as a consequence of late diagnosis, is associated with worse outcome [15] . In our centre, ART was started more often in IDUs with TB, usually because of their presentation with severe immunosuppression. The limited information regarding adherence to ART in our patient population makes it difficult to comment on its impact, although it is perhaps relevant that survival was significantly worse in patients with TB coinfection over the first 2 years from HIV diagnosis (Fig. 2a) .
We found the profile of a HIV/TB-coinfected IDU to be an unemployed urban male, with a low level of education, who was using mainly ethnobotanical drugs. Smoked drugs were more often used in combination with injectables by TB patients. This is in agreement with literature highlighting the association between inhaled crack cocaine and smearpositive TB possibly as a result of respiratory damage [20] .
Although the percentage of TB in IDUs was higher in patients with a history of imprisonment, this was not statistically significant. Other risk factors such as tattoos or piercings commonly reported to be associated with TB [14, 16, 21, 22] were not identified in our study.
The frequent use of injectable drugs, in particular ethnobotanicals which involve multiple administrations per day, often using unsterile injecting equipment, has been associated with a very high frequency of viral hepatitis [3] [4] [5] [6] [7] 11] . Inevitably, almost all IDUs in our study were HCV antibody positive, although HBsAg positivity was more common in IDUs without TB. This may relate to a greater proportion of these patients reporting multiple partners or unprotected sexual intercourse. The data suggesting that TB-infected IDUs reported fewer sexual partners than non-TB-infected IDUs might be explained by the former group being less social, and hence possibly less likely or able to seek health care and/or be advised to do so by others when unwell. This would be consistent with the worse immunological status and higher HIV viral load found in the TB-infected IDUs at the time of their HIV diagnosis.
Studies performed in Eastern Europe have highlighted the possible association between injecting drug use, HIV infection and MDR TB [23] . Over the last decade, drugresistant TB has become a particular challenge for TB management. This has had a major impact on survival in IDUs [24] . The number of MDR and XDR TB cases in our study increased annually, spiking in the last year of this report. This is a particular concern as patients with drug resistance are harder to treat, and likely therefore to be infectious to others for longer. The dissemination of resistant TB strains among vulnerable groups, as well as the general population, represents a challenge for health care systems that are already struggling to manage patients with complex psycho-social issues. The higher costs of treatment of such patients do not necessarily translate into better outcomes. Despite the greater availability of ART in Eastern European countries over the last decade, mortality among HIV-infected patients with drugresistant TB has been reported to approach 30% [25, 26] .
Limitations
Despite our hospital being a large, national centre providing care to HIV-infected IDUs from all over Romania, this was a single-site study performed over a relatively short period of time. However, we are unaware of similar data on HIV and TB infection in Romanian IDUs.
The diagnosis of TB was definitive (confirmed by positive culture) in over half of our patients. This is in line with the percentage of definitive diagnoses reported by ECDC in 2013 for all TB cases in both Europe (almost 60%) and Romania (65.2%) [2] . A limitation of our study is that blood CD4 cell counts and HIV load were not available for all study subjects at HIV diagnosis. Also, the recording of antiretroviral use was incomplete, making it difficult to compare our data with those from other countries, although we are aware that this is a common challenge in Eastern Europe [25, 26] . Finally, we had no post-mortem histopathological diagnoses to confirm the cause of death in our IDU population.
Conclusions
TB prevalence in HIV-infected Romanian IDUs has increased over the last decade and significant TB drug resistance has emerged as a particular issue. The management of IDUs with HIV infection is difficult because of their severe addiction and/or neuro-psychiatric disorders plus possible poor adherence to ART. Under these circumstances, we believe that strengthening HIV transmission prevention methods, particularly in identified risk groups, while addressing the surge in TB is vital. A multidisciplinary approach, including national policies for routine HIV and hepatitis testing for IDUs, improvement of harm-reduction programmes (needle/syringe exchange programmes and opioid substitution treatment services), and linkage to care and treatment for HIV infection, viral hepatitis and TB, needs to be implemented urgently if we are to improve outcomes in this vulnerable patient population.
